RXRA and metabolic dysfunction-associated steatotic liver disease: Previous studies have found that PPARα/RXRα signaling can participate in human metabolic diseases by regulating oxidative stress, lipid metabolism, and inflammatory pathways, which suggests that it is possible that hepatokines influence the development of NAFLD and NASH via PPARα/RXRα signaling pathway.